Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 43Carcinoma, Hepatocellular 19Rectal Neoplasms 10Colonic Neoplasms 10Neoplasm Metastasis 9Gastrointestinal Stromal Tumors 8Sarcoma 5Ovarian Neoplasms 5Melanoma 4Cholangiocarcinoma 4Pancreatic Neoplasms 3Osteosarcoma 3Liver Neoplasms 3Glioblastoma 3Stomach Neoplasms 2Neoplasms 2Lung Neoplasms 2Gallbladder Neoplasms 2Fatigue 2Esophageal Neoplasms 2Colorectal Cancer Metastatic 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Adenocarcinoma 2Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1Thyroid Neoplasms 1Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1

Interventions

Paclitaxel 4Oxaliplatin 4Cisplatin 4Radiotherapy 3Ocoxin 3Folfox protocol 3pembrolizumab 2camrelizumab 2apatinib 2anlotinib 2Sunitinib 2Sorafenib 2Imatinib Mesylate 2Gemcitabine 2Fluorouracil 2Drug Therapy 2Capecitabine 2Bevacizumab 2tislelizumab 1sintilimab 1regorafenib 1pyrotinib 1pemigatinib 1genexol-PM 1durvalumab 1donafenib 1copanlisib 1atezolizumab 1alectinib 1Tretinoin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Digestive System Neoplasms × regorafenib × Clear all
NCT06099821 2023-10-26

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Peking University Cancer Hospital & Institute

Phase 2 Recruiting
39 enrolled
Gastrointestinal

Digestive System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡